IP Library Granted Patent US 9,598,712
Granted Patent B2
US 9,598,712 · App. 14/384,233 · Granted Mar 21, 2017

Chemical process for preparing spiroindolones and intermediates thereof

Inventors: Michael Crowe (Redwood City, CA); Michael Foulkes (Redwood City, CA); Giancarlo Francese (Basel, CH); Dominique Grimler (Basel, CH); Ernst Kuesters (Basel, CH); Kurt Laumen (Basel, CH); Yunzhong Li (Changshu, CN); Changxue Lin (Changshu, CN); Jovana Nazor (Redwood City, CA); Thomas Ruch (Basel, CH); Derek Smith (Redwood City, CA); Shiwei Song (Redwood City, CA); Shangjun Teng (Changshu, CN)
Assignee: Novartis AG
C12P17/10C07D209/12C07D209/14C07D209/34C07D209/38C07D405/06C07D471/20C12N9/1096Y02P20/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,598,712
App. No.
14/384,233
Granted
Mar 21, 2017
Kind
B2
Abstract

The present invention relates to processes and intermediates useful for the manufacture of spiroindolone compounds such as (1′R,3′S)-5,7′-dichloro-6′-fluoro-3′-methyl-2′,3′,4′,9′-tetrahydrospiro[indoline-3,1′-pyrido[3,4-b]indol]-2-one and salts and hydrates and solvates thereof.

Claims (19)

1. A process for preparing a compound of formula (II), or a salt, solvate, or hydrate thereof,

Comprising enzymatically converting a compound of formula (I) to compound of formula (II), or a salt, solvate or hydrate thereof,

wherein:

the enzyme is SEQ ID NO: 134

the dashed line is a bond or absent;

A is selected from C═O or C═NH; or when the dashed line is a double bond A-R 8 is:

R a is C 1-6 alkyl;

R 1 is H, —CH 3 ,

R 4 and R 7 are each, independently, H or —Cl;

R 5 is H, —OH, —CH 3 , —OCH 3 , —F, —Cl, —CF 3 or —CN;

R 6 is H, —OH, —OCH 3 , —F or —Cl;

R 8 is H, —CH 3 , —CH 2 CH 3 , —CH 2 OH, —CO 2 H, —CO 2 CH 2 CH 3 or —CF 3 ; and

n is 1 or 2.

2. The process of claim 1 , wherein R 5 and R 6 are fluoro when: R 8 is —CH 3 , and n is 1.

3. The process of claim 1 , wherein R 5 and R 6 are each, independently, fluoro or chloro, when: R 8 is —CH 3 , and n is 1.

4. The claim 1 , wherein R 5 and R 6 are hydrogen when: R 8 is —CH 3 and n is 1.

5. The process of claim 1 , wherein R 5 is fluoro when; n is 1, and R 6 is hydrogen.

6. The process of claim 1 , wherein the compound of formula (II) is of formula (IIA), or a salt or solvate or hydrate thereof,

7. The process according to claim 1 or 6 , wherein the compound of formula (I) is a compound of formula (IA) or a salt or hydrate, or solvate thereof,

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2014
From: CROWE, MICHAEL; NAZOR, JOVANA; SMITH, DEREK; SONG, SHIWEI
To: CODEXIS, INC.
Reel/Frame 033777/0379 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2014
From: CODEXIS, INC.
To: NOVARTIS PHARMA AG
Reel/Frame 033777/0474 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2014
From: NOVARTIS PHARMA AG
To: NOVARTIS PHARMACEUTICALS CORPORATION
Reel/Frame 033777/0585 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2014
From: LI, YUNZHONG; LIN, CHANGXUE; TENG, SHANGJUN
To: SUZHOU NOVARTIS PHARMA TECHNOLOGY CO., LTD.
Reel/Frame 033777/0831 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2014
From: SUZHOU NOVARTIS PHARMA TECHNOLOGY CO., LTD.
To: NOVARTIS AG
Reel/Frame 033777/0986 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2014
From: FOULKES, MICHAEL; FRANCESE, GIANCARLO; GRIMLER, DOMINIQUE; KUESTERS, ERNST; LAUMEN, KURT; RUCH, THOMAS
To: NOVARTIS PHARMA AG
Reel/Frame 033778/0310 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2014
From: NOVARTIS PHARMA AG
To: NOVARTIS AG
Reel/Frame 033778/0658 →
Priority Claims (1)
WO PCT/CN2012/000359 · Mar 23, 2012 · international
Continuity (1)
Related Publication 20150045562A1 · Feb 12, 2015